Agios Pharmaceuticals (AGIO) Gains from Investment Securities (2012 - 2026)
Agios Pharmaceuticals (AGIO) reported Gains from Investment Securities of $4000.0 for Q1 2026, down 97.87% on a YoY basis from $188000.0 in Q1 2025, and up 100.25% quarter-over-quarter from -$1.6 million in Q4 2025.
Agios Pharmaceuticals (AGIO) Gains from Investment Securities (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals has reported Gains from Investment Securities for 14 years, with the latest figure at $4000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 97.87% year-over-year to $4000.0; the trailing twelve-month figure through Mar 2026 stood at -$189000.0 (down 100.43% YoY), and the FY2025 full-year result was -$5000.0, down 100.01% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $4000.0, up from -$1.6 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $43.1 million in Q4 2024, with the low at -$1.6 million in Q4 2025.
- Historically, Gains from Investment Securities has averaged $2.7 million across 5 years, with a median of $82000.0 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities plunged 609.52% — and 2024, when it jumped 15776.73%.
- Agios Pharmaceuticals' Gains from Investment Securities stood at $83000.0 in 2022, then slumped by 431.33% to -$275000.0 in 2023, then jumped by 15776.73% to $43.1 million in 2024, then slumped by 103.65% to -$1.6 million in 2025, then soared by 100.25% to $4000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $4000.0 (Q1 2026), -$1.6 million (Q4 2025), and $65000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | -1.57 Mn |
| Dec 31, 2025 | -1.57 Mn |
| Sep 30, 2025 | 65,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 188,000.00 |
| Mar 31, 2025 | 188,000.00 |
| Dec 31, 2024 | 43.11 Mn |
| Dec 31, 2024 | 43.11 Mn |
| Sep 30, 2024 | 642,000.00 |
| Sep 30, 2024 | 642,000.00 |
| Jun 30, 2024 | -78,000.00 |
| Jun 30, 2024 | -78,000.00 |
| Mar 31, 2024 | -525,000.00 |
| Mar 31, 2024 | -525,000.00 |
| Dec 31, 2023 | -275,000.00 |
| Dec 31, 2023 | -275,000.00 |